134 related articles for article (PubMed ID: 18039990)
1. Increasing outpatient fluoroquinolone exposure before tuberculosis diagnosis and impact on culture-negative disease.
Gaba PD; Haley C; Griffin MR; Mitchel E; Warkentin J; Holt E; Baggett P; Sterling TR
Arch Intern Med; 2007 Nov; 167(21):2317-22. PubMed ID: 18039990
[TBL] [Abstract][Full Text] [Related]
2. Fluoroquinolone resistance in patients with newly diagnosed tuberculosis.
Ginsburg AS; Hooper N; Parrish N; Dooley KE; Dorman SE; Booth J; Diener-West M; Merz WG; Bishai WR; Sterling TR
Clin Infect Dis; 2003 Dec; 37(11):1448-52. PubMed ID: 14614666
[TBL] [Abstract][Full Text] [Related]
3. Empirical treatment of community-acquired pneumonia and the development of fluoroquinolone-resistant tuberculosis.
Long R; Chong H; Hoeppner V; Shanmuganathan H; Kowalewska-Grochowska K; Shandro C; Manfreda J; Senthilselvan A; Elzainy A; Marrie T
Clin Infect Dis; 2009 May; 48(10):1354-60. PubMed ID: 19348594
[TBL] [Abstract][Full Text] [Related]
4. Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of duration and timing of fluoroquinolone exposure.
Devasia RA; Blackman A; Gebretsadik T; Griffin M; Shintani A; May C; Smith T; Hooper N; Maruri F; Warkentin J; Mitchel E; Sterling TR
Am J Respir Crit Care Med; 2009 Aug; 180(4):365-70. PubMed ID: 19483111
[TBL] [Abstract][Full Text] [Related]
5. Fluoroquinolone susceptibility in Mycobacterium tuberculosis after pre-diagnosis exposure to older- versus newer-generation fluoroquinolones.
van der Heijden YF; Maruri F; Blackman A; Mitchel E; Bian A; Shintani AK; Eden S; Warkentin JV; Sterling TR
Int J Antimicrob Agents; 2013 Sep; 42(3):232-7. PubMed ID: 23806638
[TBL] [Abstract][Full Text] [Related]
6. Fluoroquinolone use and risk factors for Clostridium difficile-associated disease within a Veterans Administration health care system.
McFarland LV; Clarridge JE; Beneda HW; Raugi GJ
Clin Infect Dis; 2007 Nov; 45(9):1141-51. PubMed ID: 17918075
[TBL] [Abstract][Full Text] [Related]
7. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population.
Seeger JD; West WA; Fife D; Noel GJ; Johnson LN; Walker AM
Pharmacoepidemiol Drug Saf; 2006 Nov; 15(11):784-92. PubMed ID: 16456878
[TBL] [Abstract][Full Text] [Related]
8. Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis initially treated as bacterial pneumonia.
Yoon YS; Lee HJ; Yoon HI; Yoo CG; Kim YW; Han SK; Shim YS; Yim JJ
Int J Tuberc Lung Dis; 2005 Nov; 9(11):1215-9. PubMed ID: 16333927
[TBL] [Abstract][Full Text] [Related]
9. Empirical treatment with a fluoroquinolone delays the treatment for tuberculosis and is associated with a poor prognosis in endemic areas.
Wang JY; Hsueh PR; Jan IS; Lee LN; Liaw YS; Yang PC; Luh KT
Thorax; 2006 Oct; 61(10):903-8. PubMed ID: 16809417
[TBL] [Abstract][Full Text] [Related]
10. National trends in emergency department antibiotic prescribing for elders with urinary tract infection, 1996-2005.
Caterino JM; Weed SG; Espinola JA; Camargo CA
Acad Emerg Med; 2009 Jun; 16(6):500-7. PubMed ID: 19245373
[TBL] [Abstract][Full Text] [Related]
11. [Quinolone resistance in Gram negative rods in Iceland and association with antibiotic use].
Jónsdóttir K; Kristinsson KG
Laeknabladid; 2008 Apr; 94(4):279-85. PubMed ID: 18460726
[TBL] [Abstract][Full Text] [Related]
12. Fluoroquinolone resistance in renal isolates of Mycobacterium tuberculosis.
Webster D; Long R; Shandro C; Pettipas J; Leblanc J; Davidson R; Fanning A
Int J Tuberc Lung Dis; 2010 Feb; 14(2):217-22. PubMed ID: 20074414
[TBL] [Abstract][Full Text] [Related]
13. The WHO/IUATLD diagnostic algorithm for tuberculosis and empiric fluoroquinolone use: potential pitfalls.
Sterling TR
Int J Tuberc Lung Dis; 2004 Dec; 8(12):1396-400. PubMed ID: 15636484
[TBL] [Abstract][Full Text] [Related]
14. Sputum conversion among patients with pulmonary tuberculosis: are there implications for removal of respiratory isolation?
Fortún J; Martín-Dávila P; Molina A; Navas E; Hermida JM; Cobo J; Gómez-Mampaso E; Moreno S
J Antimicrob Chemother; 2007 Apr; 59(4):794-8. PubMed ID: 17392354
[TBL] [Abstract][Full Text] [Related]
15. Impact of fluoroquinolone prophylaxis on reduced infection-related mortality among patients with neutropenia and hematologic malignancies.
Reuter S; Kern WV; Sigge A; Döhner H; Marre R; Kern P; von Baum H
Clin Infect Dis; 2005 Apr; 40(8):1087-93. PubMed ID: 15791505
[TBL] [Abstract][Full Text] [Related]
16. The rapid development of fluoroquinolone resistance in M. tuberculosis.
Ginsburg AS; Woolwine SC; Hooper N; Benjamin WH; Bishai WR; Dorman SE; Sterling TR
N Engl J Med; 2003 Nov; 349(20):1977-8. PubMed ID: 14614180
[No Abstract] [Full Text] [Related]
17. Treatment failure rates and health care utilization and costs among patients with community-acquired pneumonia treated with levofloxacin or macrolides in an outpatient setting: a retrospective claims database analysis.
Ye X; Sikirica V; Schein JR; Grant R; Zarotsky V; Doshi D; Benson CJ; Riedel AA
Clin Ther; 2008 Feb; 30(2):358-71. PubMed ID: 18343274
[TBL] [Abstract][Full Text] [Related]
18. Impact of hospital formularies on fluoroquinolone prescribing in emergency departments.
Aspinall SL; Metlay JP; Maselli JH; Gonzales R
Am J Manag Care; 2007 May; 13(5):241-8. PubMed ID: 17488189
[TBL] [Abstract][Full Text] [Related]
19. Use of fluoroquinolone antibiotics leads to tuberculosis treatment delay in a South African gold mining community.
Jeon CY; Calver AD; Victor TC; Warren RM; Shin SS; Murray MB
Int J Tuberc Lung Dis; 2011 Jan; 15(1):77-83. PubMed ID: 21276301
[TBL] [Abstract][Full Text] [Related]
20. Empiric treatment of community-acquired pneumonia with fluoroquinolones, and delays in the treatment of tuberculosis.
Dooley KE; Golub J; Goes FS; Merz WG; Sterling TR
Clin Infect Dis; 2002 Jun; 34(12):1607-12. PubMed ID: 12032896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
